David Lazar
Principal executive officer pay for David Lazar, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Grouped by exact name match across filings; distinct people sharing a name would be merged — flag it and we'll split them.
FiEE, Inc. (FIEE) FY2024–FY2024
Aligned: pay fell with the stockCAP $402,250→$402,250 while $100 invested went $43.78→$43.78
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2024 | $402,250 | $402,250 |
The company's "$100 invested" index ran $43.78 at FY2024 → $43.78 by FY2024.
TITAN PHARMACEUTICALS INC (TTNP) FY2022–FY2022
Aligned: pay fell with the stockCAP $152,250→$152,250 while $100 invested went $23.80→$23.80
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $152,250 | $152,250 |
The company's "$100 invested" index ran $23.80 at FY2022 → $23.80 by FY2022.
Cyclacel Pharmaceuticals, Inc. (CYCC) FY2025–FY2025
Aligned: pay fell with the stockCAP $66,250→$66,250 while $100 invested went $0.06→$0.06
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2025 | $66,250 | $66,250 |
The company's "$100 invested" index ran $0.06 at FY2025 → $0.06 by FY2025.
Track record
Not enough disclosed TSR endpoints to annualize a return for David Lazar yet. Pay-versus-performance disclosure only began with fiscal year 2022, so track records only cover that window.
All disclosed tenures: 0 years across 3 companies. Shown per company only: at least one stint has no usable "$100 invested" endpoints to chain through.